A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 22-26

  Cantrell, Leigh A ^a   Havrilesky, Laura ^b   Moore, Dominic T ^c   O'Malley, David ^d   Liotta, Margaret ^e   Secord, Angeles Alvarez ^b   Nagel, Christa I ^f   Cohn, David E ^d   Fader, Amanda Nickles ^g   Wallace, Amy H ^b   Rose, Peter ^e   Gehrig, Paola A ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Division of Gynecologic Oncology   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Carcinosarcoma; Early stage; MMMT; Therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UTERINE CARCINOSARCOMA; UTERUS SARCOMA;

AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 84865687098     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.020     Document Type: Article

References (26)

1. American Cancer Society Cancer facts & figures 2012 2012 American Cancer Society Atlanta
2. S. El-Nashar, and A. Mariani Uterine carcinosarcoma Clin Obstet Gynecol 54 2011 292 304
3. N. Bansal, T.J. Herzog, V.E. Seshan, P.B. Schiff, W.M. Burke, C.J. Cohen, and J.D. Wright Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior Obstet Gynecol 112 2008 64 70
4. F.J. Major, J.A. Blessing, S.G. Silverberg, C.P. Morrow, W.T. Creasman, and J.L. Currie Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study Cancer 71 1993 1702 1709
5. W.T. Creasman, C.P. Morrow, B.N. Bundy, H.D. Homesley, J.E. Graham, and P.B. Heller Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study Cancer 60 8 Suppl. 1987 2035 2041
6. F. Amant, I. Cadron, L. Fuso, P. Berteloot, E. de Jonge, and G. Jacomen Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer Gynecol Oncol 98 2005 274
7. A.P. Vaidya, N.S. Horowitz, E. Oliva, E.F. Halpern, and L.R. Duska Uterine malignant mixed Mullerian tumors should not be included in studies of endometrial carcinoma Gynecol Onc 103 2006 684 687
8. A.H. Wolfson, M.F. Brady, T. Rocereto, R.S. Mannel, Y. Lee, and R.J. Futoran A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus Gynecol Oncol 107 2007 177 185
9. N.S. Reed, C. Mangioni, H. Malmstrom, G. Scarfone, A. Poveda, and S. Pecorelli Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organization for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874) Eur J Cancer 44 2008 808 818
10. G. Sutton, J. Kauderer, L.F. Carson, S.S. Lentz, C.W. Whitney, H. Gallion Gynecologic Oncology Group Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 96 2005 630 634
11. J.D. Wright, V.E. Seshan, M. Shah, P.B. Schiff, W.M. Burke, C.J. Cohen, and T.J. Herzog The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma Am J Obstet Gynecol 199 2008 536.e1 536.e8
12. D. Clayton Smith, O. Kenneth MacDonald, and D.K. Gaffney The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma Radiother Oncol 88 2008 227 232
13. D. Nemani, N. Mitra, M. Guo, and L. Lin Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis Gynecol Oncol 111 2008 82 88
14. B.E. Greer, W.J. Koh, N. Abu-Rustum, M.A. Bookman, R.E. Bristow, and S.M. Campos Uterine neoplasms. Clinical practice guidelines in oncology J Natl Compr Canc Netw 7 2009 498 531
15. C.A. Leath, T.M. Numnmum, J.E. Kendrick, P.J. Frederick, R.P. Rocconi, and M.G. Conner Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma Int J Gynecol Cancer 19 2009 888 891
16. R.E. Kass, and A.E. Raftery Bayes factors JASA 90 430 Jun 1995 773 795
17. A.E. Raftery Bayesian model selection in social research Sociol Methodol 25 1995 111 163
18. D.G. Altman Practical statistics for medical research 1999 Chapman & Hall NY
19. SAS statistical software, Version 9.2, from the SAS Institute, Inc., Cary, NC; 2009.
20. The R Development Core Team R: a language and environment for statistical computing R is an open source statistical programming language from the R Development Core Team 2008 R Foundation for Statistical Computing Vienna, Austria 3-900051-07-0 URL http://www.R-project.org)
21. WHO Consultation of Obesity Obesity: preventing and managing the global epidemic 1998 World Health Organization Geneva Geneva, 3-5 June 1997
22. J.R. van Nagell, M.B. Hanson, E.S. Donaldson, and H.H. Gallion Adjuvant vincristine, dactinomycin and cyclophosphamide therapy in stage I uterine sarcomas Cancer 57 1986 1451 1454
23. R.E. Hempling, M.S. Piver, and T.R. Baker Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma: a prospective trial Am J Clin Oncol 18 1995 282 286
24. V. Makker, N.R. Abu-Rustum, K.M. Alektiar, C.A. Aghajanian, Q. Zhou, and A. Iasonos A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma Gynecol Oncol 111 2008 249 254
25. J. Gonzalez Bosquet, S.A. Terstriep, W.A. Cliby, M. Brown-Jones, J.S. Kaur, and K.C. Podratz The impact of multimodal therapy on survival for uterine carcinosarcomas Gynecol Oncol 116 2010 419 423
26. T.P. Manolitsas, G.V. Wain, K.E. Williams, M. Freidlander, and N.F. Hacker Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus Cancer 91 2001 1437 1443